Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Search
Outside the lab…inside the family
We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
Building lasting partnerships for a better future
Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
Niha Agarwalla
My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!
Our Stories
Our Stories
Meet our Team
Meet Our Team
Sustainable Development - Our Commitment
Our Commitment
Partnering-Oncology-Cancer-Imm-HP.pdf
Colorectal_Cancer_Infographic.pdf
Science Stories
Science Stories
Open Innovation at Boehringer Ingelheim
Open Innovation at Boehringer Ingelheim
Working Together in Human Health
Working Together in Human Health
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
Respiratory
Respiratory
Science & Innovation
Our Science
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Contact Us
Contact Us
Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US
Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.
NASH
NASH
Animal Health Innovation
Animal Health Innovation
Our Science Focus
Our Science Focus
Veterinary Public Health
Veterinary Public Health
Occupational Health and Safety
Occupational Health and Safety
BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US
BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.
Obesity
Obesity